Methylphenidate Alternova (Methylphenidate Hydrochloride)

Methylphenidate inhibits the reuptake of dopamine and norepinephrine at neuronal synapses, increasing their extracellular concentrations. The heightened catecholamine activity enhances signaling in brain circuits that regulate attention, motivation, and arousal, which accounts for its therapeutic benefits in ADHD and narcolepsy.

The appropriate dose of Methylphenidate Alternova is individualized by the prescribing clinician based on the patient’s age, diagnosis, response to therapy, and any relevant medical conditions. Dosage adjustments are made according to clinical judgment and patient monitoring.

Methylphenidate is classified as pregnancy category B1, indicating no evidence of fetal risk in animal studies but limited human data. Use during pregnancy or lactation should only occur if the potential benefit justifies the potential risk, and always under medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Methylphenidate Alternova belongs to the central nervous system stimulant class, similar to amphetamine‑based products. Both increase dopamine and norepinephrine activity, but methylphenidate primarily blocks reuptake, whereas amphetamines also promote release. Clinical response, side‑effect profile, and individual tolerability guide the choice between them.

Store the tablets at ambient temperature, below 25 °C (77 °F). Keep them in the original packaging, protect from moisture, heat, and direct sunlight. Do not store in the bathroom or other humid environments.

Methylphenidate Alternova is taken orally as a tablet. It should be swallowed whole with a glass of water, with or without food, as directed by the prescriber. Do not crush, chew, or split the tablet unless specifically instructed.

Serious risks include cardiovascular events such as hypertension or tachycardia, the emergence of psychotic symptoms (hallucinations, delusions), and severe allergic reactions like anaphylaxis. Patients should be monitored closely for these events, especially during treatment initiation or dose changes.

Methylphenidate Alternova is contraindicated in individuals with known hypersensitivity to methylphenidate, those taking monoamine oxidase inhibitors (MAOIs) within the past 14 days, and patients with severe cardiovascular disorders, uncontrolled hypertension, or a history of psychosis. It should also be used with caution in patients with anxiety, glaucoma, or seizure disorders.